Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
BDSX logo BDSX
Upturn stock ratingUpturn stock rating
BDSX logo

Biodesix Inc (BDSX)

Upturn stock ratingUpturn stock rating
$0.45
Last Close (24-hour delay)
Profit since last BUY7.14%
upturn advisory
Consider higher Upturn Star rating
BUY since 26 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/28/2025: BDSX (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

6 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $1.75

1 Year Target Price $1.75

Analysts Price Target For last 52 week
$1.75 Target price
52w Low $0.17
Current$0.45
52w High $2

Analysis of Past Performance

Type Stock
Historic Profit -49.94%
Avg. Invested days 28
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/28/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 65.46M USD
Price to earnings Ratio -
1Y Target Price 1.75
Price to earnings Ratio -
1Y Target Price 1.75
Volume (30-day avg) 6
Beta 0.98
52 Weeks Range 0.17 - 2.00
Updated Date 08/29/2025
52 Weeks Range 0.17 - 2.00
Updated Date 08/29/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.26

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date 2025-08-07
When -
Estimate -0.07
Actual -0.08

Profitability

Profit Margin -53.66%
Operating Margin (TTM) -48.42%

Management Effectiveness

Return on Assets (TTM) -20.81%
Return on Equity (TTM) -219.68%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 116870128
Price to Sales(TTM) 0.85
Enterprise Value 116870128
Price to Sales(TTM) 0.85
Enterprise Value to Revenue 1.53
Enterprise Value to EBITDA -2.72
Shares Outstanding 146632992
Shares Floating 62040571
Shares Outstanding 146632992
Shares Floating 62040571
Percent Insiders 52.13
Percent Institutions 24.32

ai summary icon Upturn AI SWOT

Biodesix Inc

stock logo

Company Overview

overview logo History and Background

Biodesix, Inc. was founded in 2005 and is a molecular diagnostics company that develops and commercializes tests for lung disease. It went public in 2020.

business area logo Core Business Areas

  • Lung Diagnostic Tests: Develops and commercializes blood-based diagnostic tests for lung cancer and other lung diseases. Focuses on improving patient outcomes through earlier and more accurate diagnoses.

leadership logo Leadership and Structure

The leadership team includes Scott Hutton (CEO) and other executives. The company has a standard corporate structure with departments for R&D, commercial operations, and finance.

Top Products and Market Share

overview logo Key Offerings

  • Nodify Lung Nodule Risk Assessment: A blood-based test that helps physicians assess the risk of malignancy in lung nodules. Market share data is not publicly available for this specific test. Competitors include Veracyte and other molecular diagnostics companies in the lung cancer space.
  • LungStrat Dx EGFR Mutation Test: Identifies EGFR mutations in lung cancer patients. Market share data is not publicly available for this specific test. Competitors include Roche, Thermo Fisher Scientific, and other companies offering EGFR testing solutions.

Market Dynamics

industry overview logo Industry Overview

The molecular diagnostics market is growing due to the increasing prevalence of diseases like cancer and the demand for personalized medicine.

Positioning

Biodesix aims to be a leader in lung cancer diagnostics by providing innovative blood-based tests that improve patient care.

Total Addressable Market (TAM)

The total addressable market for lung cancer diagnostics is estimated to be in the billions of dollars. Biodesix is positioned to capture a share of this market with its portfolio of tests.

Upturn SWOT Analysis

Strengths

  • Proprietary diagnostic technologies
  • Focus on lung diseases
  • Established commercial infrastructure

Weaknesses

  • Limited financial resources compared to larger competitors
  • Dependence on reimbursement for test adoption
  • Relatively small market capitalization

Opportunities

  • Expanding the test menu to cover other lung diseases
  • Strategic partnerships with pharmaceutical companies
  • Increasing awareness of the benefits of blood-based diagnostics

Threats

  • Competition from larger diagnostic companies
  • Changes in reimbursement policies
  • Clinical trial failures

Competitors and Market Share

competitor logo Key Competitors

  • Veracyte (VCYT)
  • Exact Sciences (EXAS)
  • Guardant Health (GH)

Competitive Landscape

Biodesix is a smaller player compared to competitors like Veracyte and Exact Sciences. Its competitive advantage lies in its focus on lung diseases and its proprietary diagnostic technologies. However, it faces challenges related to limited financial resources and reimbursement.

Growth Trajectory and Initiatives

Historical Growth: Biodesix's historical growth has been driven by the adoption of its lung diagnostic tests.

Future Projections: Future growth is expected to be driven by expanding the test menu, strategic partnerships, and increasing market penetration.

Recent Initiatives: Recent initiatives include expanding the commercial team, investing in R&D, and pursuing strategic partnerships.

Summary

Biodesix is a molecular diagnostics company focused on lung diseases. It has proprietary technologies and a growing portfolio of tests. However, it faces competition from larger companies and challenges related to reimbursement and financial resources. Strategic partnerships and test menu expansion are crucial for future growth.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Website
  • SEC Filings
  • Analyst Reports
  • Industry Reports

Disclaimers:

The information provided is for informational purposes only and should not be considered investment advice. Market share data is based on estimates and may not be precise. Financial data and analyst estimates are subject to change.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Biodesix Inc

Exchange NASDAQ
Headquaters Louisville, CO, United States
IPO Launch date 2020-10-28
President, CEO & Director Mr. Scott Hutton
Sector Healthcare
Industry Diagnostics & Research
Full time employees 273
Full time employees 273

Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR, GeneStrat NGS, and VeriStrat tests markets as part of IQLung testing strategy, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to guide treatment decisions. In addition, the company provides diagnostic solutions, including translational research, initial biomarker discovery, assay design, development, and validation, testing of clinical trial samples, regulatory, reimbursement, commercialization, and logistical support services for biopharmaceutical, life sciences, and diagnostic companies. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.